- Home
- PFO vs PLX Comparison
PFO vs PLX Comparison
Compare PFO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFO
- PLX
- Stock Information
- Founded
- PFO 1991
- PLX 1993
- Country
- PFO United States
- PLX United States
- Employees
- PFO N/A
- PLX N/A
- Industry
- PFO Finance Companies
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFO Finance
- PLX Health Care
- Exchange
- PFO Nasdaq
- PLX Nasdaq
- Market Cap
- PFO 116.6M
- PLX 122.6M
- IPO Year
- PFO N/A
- PLX 1998
- Fundamental
- Price
- PFO $9.14
- PLX $1.40
- Analyst Decision
- PFO
- PLX Strong Buy
- Analyst Count
- PFO 0
- PLX 1
- Target Price
- PFO N/A
- PLX $15.00
- AVG Volume (30 Days)
- PFO 31.8K
- PLX 640.7K
- Earning Date
- PFO 01-01-0001
- PLX 08-13-2025
- Dividend Yield
- PFO 6.51%
- PLX N/A
- EPS Growth
- PFO N/A
- PLX N/A
- EPS
- PFO N/A
- PLX 0.05
- Revenue
- PFO N/A
- PLX $59,764,000.00
- Revenue This Year
- PFO N/A
- PLX $65.02
- Revenue Next Year
- PFO N/A
- PLX $57.34
- P/E Ratio
- PFO N/A
- PLX $28.96
- Revenue Growth
- PFO N/A
- PLX 0.18
- 52 Week Low
- PFO $6.90
- PLX $0.82
- 52 Week High
- PFO $8.51
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- PFO 59.24
- PLX 30.38
- Support Level
- PFO $9.03
- PLX $1.52
- Resistance Level
- PFO $9.17
- PLX $1.65
- Average True Range (ATR)
- PFO 0.14
- PLX 0.08
- MACD
- PFO 0.00
- PLX 0.02
- Stochastic Oscillator
- PFO 95.69
- PLX 17.19
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.